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Lipid nanoemulsions and liposomes 
improve photodynamic treatment efficacy 
and tolerance in CAL-33 tumor bearing  
nude mice
Doris Hinger1* , Susanna Gräfe2, Fabrice Navarro3,4, Bernhard Spingler5, Devaraj Pandiarajan5, Heinrich Walt6, 
Anne‑Claude Couffin3,4 and Caroline Maake1
Abstract 
Background: Photodynamic therapy (PDT) as promising alternative to conventional cancer treatments works by 
irradiation of a photosensitizer (PS) with light, which creates reactive oxygen species and singlet oxygen (1O2), that 
damage the tumor. However, a routine use is hindered by the PS’s poor water solubility and extended cutaneous 
photosensitivity of patients after treatment. In our study we sought to overcome these limitations by encapsulation of 
the PS m‑tetrahydroxyphenylchlorin (mTHPC) into a biocompatible nanoemulsion (Lipidots).
Results: In CAL‑33 tumor bearing nude mice we compared the Lipidots to the existing liposomal mTHPC nanofor‑
mulation Foslip and the approved mTHPC formulation Foscan. We established biodistribution profiles via fluorescence 
measurements in vivo and high performance liquid chromatography (HPLC) analysis. All formulations accumulated in 
the tumors and we could determine the optimum treatment time point for each substance (8 h for mTHPC, 24 h for 
Foslip and 72 h for the Lipidots). We used two different light doses (10  and 20 J/cm2) and evaluated immediate PDT 
effects 48 h after treatment and long term effects 14 days later. We also analyzed tumors by histological analysis and 
performing reverse transcription real‑time PCR with RNA extracts. Concerning tumor destruction Foslip was superior 
to Lipidots and Foscan while with regard to tolerance and side effects Lipidots were giving the best results.
Conclusions: We could demonstrate in our study that nanoformulations are superior to the free PS mTHPC. The 
development of a potent nanoformulation is of major importance because the free PS is related to several issues such 
as poor bioavailability, solubility and increased photosensibility of patients. We could show in this study that Foslip is 
very potent in destroying the tumors itself. However, because the Lipidots’ biocompatibility is outstanding and supe‑
rior to the liposomes we plan to carry out further investigations and protocol optimization. Both nanoformulations 
show great potential to revolutionize PDT in the future.
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Background
Photodynamic therapy (PDT) has received more atten-
tion in recent years as attractive alternative to conven-
tional cancer treatments such as chemotherapy, surgery 
or radiotherapy [1, 2]. The principle of photodestruction 
on which it relies on works by exposure of a so called 
photosensitizer (PS) to light of an appropriate wave-
length, which in turn depends on the kind of PS used. 
The PS reacts with oxygen upon irradiation and gener-
ates reactive oxygen species (ROS) and singlet oxygen 
(1O2) which damage surrounding tissue [3–5]. However, 
the short lifetime of singlet oxygen (<0.04 µs) and low dif-
fusion potential with a small radius of action (0.02  µm) 
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limits the damage to the irradiated spot [6]. In addition to 
this direct killing of malignant cells [7] tumor destruction 
can also be accomplished by targeting the tumor associ-
ated vessels [8]. However, a third possibility is to create 
longer lasting effects via stimulation of the immune sys-
tem which subsequently may prevent tumor recurrence 
[9].
PDT is a strictly local modality that offers certain 
advantages over established anti-cancer regimes. It is 
e.g. minimally invasive, does not have a maximal lifetime 
dose and can therefore be repeated [1], gives an excellent 
cosmetic and functional outcome [10], does not produce 
drug resistance [11], and is not associated with severe 
systemic side effects [12]. PSs are preferentially taken 
up by malignant cells and therefore exhibit an inherent 
selectivity [13]. For this reason PSs can also be used as 
imaging probes in photodiagnosis (PDD) [14]. However, 
the selectivity leaves still room for improvement. The 
currently most widely used PSs are porphyrin deriva-
tives. In an attempt to improve their optical properties 
modifications to the porphyrin structure have been made 
and led to the discovery of several second generation PSs 
like phthalocyanines [15] and chlorins [16]. The power-
ful chlorin PS m-tetrahydroxyphenylchlorin (mTHPC) is 
a well characterized substance and was highly successful 
in various in vitro, in vivo studies and clinical trials which 
has ultimately led to its approval for palliative treatment 
of head and neck cancer in Europe [17–20]. Although 
very promising its routine use in the clinic is hampered 
by poor water solubility which leads to aggregation, prob-
lematic systemic administration and suboptimal biodis-
tribution. Moreover extended photosensitivity of patients 
after treatment impairs applicability [5, 21].
A possible solution to these drawbacks can be offered 
by encapsulation of PSs into nanocarriers. With this 
approach several problems could be tackled at once. First 
of all the solubility can be drastically improved, easing 
intravenous injections. Furthermore cancer selectivity 
could be increased by passive targeting, profiting from 
the enhanced permeability and retention effect (EPR) 
of nanoparticles in solid tumors [22]. Due to the high 
payload of nanoformulations, accumulation of greater 
pharmacological PS doses within the tumor may be facil-
itated, which could improve PDT effects by lowering the 
risk of an unwanted photosensitivity of healthy tissues, 
such as the skin.
We recently developed a biocompatible nanoemul-
sion (Lipidots) [23] as carrier for mTHPC with excel-
lent optical properties which we subsequently tested in 
two in  vitro studies [24, 25]. It could be demonstrated 
that Lipidots can significantly lower the dark toxicity 
of mTHPC while maintaining its photodynamic activ-
ity. In the course of our research we identified the most 
promising Lipidot formulation which we decided to fur-
ther test in vivo.
In the present study we compared this novel mTHPC 
nanoemulsion (Lipidots) with a liposomal mTHPC for-
mulation (Foslip) [26], which has been shown to pro-
duce promising results with regard to tumor destruction 
in cats [27, 28], and the approved mTHPC formulation 
(Foscan), in CAL-33 tumor bearing nude mice.
Methods
Drug and nanoparticle preparation
MTHPC and the liposomal mTHPC formulation Fos-
lip were obtained from Biolitec Research GmbH, Jena, 
Germany as powder. A stock solution of 1 mg/mL Fos-
can was prepared by dissolving the mTHPC powder in 
a 40/60 ethanol/propylene glycol mixture and filtered 
through a syringe filter (0.22 µm pore size; TPP, Trasa-
dingen, Switzerland). Foslip (20  mg/mL DPPC/DPPG, 
2.2  mM mTHPC, 50  mg/mL Glucose) was reconsti-
tuted with sterile water, giving a stock solution of 
1.5 mg/mL (≙2.2 mM) mTHPC content, with an aver-
age particle size of 135  nm and a polydispersity index 
(PDI) of 0.089. A nanoemulsion containing mTHPC 
(Lipidots, 50  mg/mL lipid, 1.06  mM mTHPC) with an 
average particle diameter of 50  nm and a PDI of 0.17 
was prepared according to Delmas et al. [23] and Nav-
arro et al. [24].
Briefly, Lipidots were manufactured by selecting the 
suitable weight ratios of core/shell excipients to design 
50  nm diameter nanoparticles. The dispersion is com-
posed of 37.5  % (w/w) of lipid phase (with a lecithin/
PEG surfactant weight ratio of 0.19 and a surfactant/core 
weight ratio of 1.20). The Lipidots were loaded with 920 
molecules of mTHPC/particle. MTHPC was incorpo-
rated into the lipid mixture as a concentrated solution in 
ethyl acetate and after vacuum elimination of organic sol-
vent, the oily phase was added to the aqueous phase and 
emulsification was performed as previously described 
[24]. The mTHPC concentrations were determined by 
high-performance liquid chromatography (HPLC) anal-
ysis. Separation was achieved on a Sunfire C18 column 
(250  mm  ×  4.6  mm, i.d. 5  µm) at 30  °C. The mTHPC 
compound was eluted at 2.10  min using a isocratic 
mobile phase of acetonitrile/H2O trifluoroacetic acid, 
0.1 %: 9/1 at 1 mL/min flow rate after injection of 30 µL. 
The UV detection is operated at 425  nm. The mTHPC 
concentrations were assessed using a calibration curve 
in the range of 1–12 µg/mL. Physicochemical characteri-
zation data of Lipidots can be found in the supplements 
(Additional file 1: Table S1).
All solutions were stored at four degrees Celsius in the 
dark and further diluted with sterile phosphate buffered 
saline (PBS) for injection (0.15 mg/kg mTHPC).
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If not otherwise indicated, all chemicals were pur-
chased from Sigma-Aldrich, Buchs, Switzerland.
Cell culture
CAL-33, tongue squamous cell carcinoma cells (DSMZ, 
Braunschweig, Germany), were grown in RPMI-1640 
medium without phenol red and with 10  % fetal calf 
serum (FCS), 2 mM Glutamax (Life Technologies, Carls-
bad, USA), 1 % Penicillin/Streptomycin as supplements. 
Cells were kept in 75 cm2 cell culture flasks at 5 % CO2 
and 37 °C. Cell counting was performed with a Neubauer 
chamber (Laboroptik Ltd., Lancing, UK) on an aliquot of 
cells after staining with 0.1 % (w/v) nigrosin in PBS.
Husbandry conditions of mice & tumor model
Female immune deficient CD1-Foxn1nu nude mice 
(4-6  weeks old) were obtained from Charles River, 
Sulzfeld, Germany. The mice were kept as groups of 5 in 
individually ventilated cages (IVC) under specific patho-
gen free (SPF) conditions and provided with food and 
water ad  libitum.To establish the tumor model 9 mice 
each were subcutaneously injected into the right flank 
with 1.0 ×  106, 1.5 ×  106 or 2.0 ×  106 CAL-33 cells in 
0.1 mL ringer lactate (Kantonsapotheke, Zurich, Switzer-
land) using a 26 G needle and one mL syringe (B. Braun, 
Melsungen, Germany). The animals were examined at 
least every third day for up to 42  days. Upon examina-
tion the mice were weighed and scored for abnormalities 
in behavior and appearance. Tumor sizes were measured 
with a Vernier caliper.
All animal experiments were implemented with 
approval of the Swiss cantonal ethics committee for ani-
mal experiments (No. 156/2012).
Biodistribution studies
To determine pharmacokinetics Foscan, Foslip and Lipi-
dots were injected intravenously into 10 mice each at a 
final concentration of 0.15  mg mTHPC/kg bodyweight 
(bw). Fluorescence measurements were carried out 
four, 8, 12, 24, 48 and 72 h after drug injection, by press-
ing the optic fiber of a spectrometer (PDT fluorometer; 
JETI Technische Instrumente GmbH, Jena, Germany) on 
three different spots on the tumor while holding the mice 
restrained. Three different spots on the skin were also 
analyzed as a reference. After the last measurement the 
mice were sacrificed and the tissues (tumor, skin, liver, 
spleen, kidney) were weighed, cut in small pieces and 
snap frozen in liquid nitrogen. For HPLC analysis the tis-
sue was freeze dried (Christ Freeze drying system Alpha 
1–4 LSC). The resulting powdered tissue was weighed 
and approximately 10–20  mg was transferred to a two 
milliliter reaction tube. Then 1.5 mL of methanol:DMSO 
(3:5, v:v) was added followed by immediate mixing for 
three times five sec using a vortex mixer (Merck Eurolab, 
MELB 1719) operating at 2400 rpm and then incubated 
at 60  °C while continuously shaking for at least 12  h. 
All samples were then spun at 16,000g in a centrifuge 
(Microfuge, Heraeus, Germany) for 5 min. One milliliter 
of each supernatant was transferred to a HPLC vial and 
analysed by HPLC.The HPLC system consisted of the 
solvent module “System Gold 126” (Beckman Coulter, 
Brea, USA), autosampler “Triathlon” (Spark), fluores-
cence detector “RF-10A XL” (Shimadzu, Kyoto, Japan) 
with SS420x interface set for excitation wavelength at 
410  nm and for emission wavelength at 654  nm, online 
degasser (ERC3415 alpha, ERC), column thermostat Jet-
Stream Plus set at 30 °C (Thermotechnic Products), col-
umn LiChroCART250-4 with Purospher STAR RP-18 
endcapped and guard column LiChroCART4-4 with 
Purospher STAR RP-18e endcapped (Merck). The mobile 
phase was composed of acetonitril: 0.1  % trifluoro-
acetic acid in water (57.5:42.5 v/v) and the flow rate set 
at 1 mL/min. The retention time for mTHPC was about 
10 min and the injection volume was 50 µL. The measur-
ing range was from 0.25 to100  pg/µL (r2 =  0.9998) and 
the detection limit 0.05 pg/µL. The software used was 32 
Karat Software, Version 5.0, Build 1021 (Beckman Coul-
ter). The tissue concentration of mTHPC was determined 
from a calibration curve constructed by plotting the peak 
height of mTHPC standard solutions versus their con-
centrations. The calibration was linear within this range.
In vivo PDT
Before treatment 90 tumor-bearing mice were injected 
subcutaneously with 1.5  mg/kg bw of the painkiller 
Metacam (Kantonsapotheke). Subsequently they were 
intravenously injected with one of the drug formula-
tions (≙0.15 mg mTHPC/kg bw) and treated at the opti-
mum time point according to the biodistribution study. 
For laser irradiation the mice were covered with a sur-
gical drape, leaving only the tumor unprotected (≙ an 
irradiation area of 1.5  cm in diameter). Mice were held 
restrained tightly and irradiated with a Ceralas PDT laser 
652 (Biolitec) for either 100 or 200  s (≙10 or 20  J/cm2; 
100 mW/cm2). To monitor treatment effects tumor sizes 
were measured with a Vernier Caliper every 3 days and 
all mice were photographed with an 8 MP camera (Sam-
sung, Seoul, South Korea) before treatment and up to 
14 days later.
Histology and Immunohistochemistry
In order to screen for short term and long term PDT 
effects 48 h and 14 days after laser irradiation half of the 
mice (n =  45) were sacrificed in each group. Liver, kid-
ney, spleen and tumor were taken and rinsed with PBS. 
The organs were subsequently fixed with four per cent 
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formaldehyde (FA)/PBS for 12 h and transferred to PBS 
or snap frozen in liquid nitrogen. FA fixed samples were 
dehydrated with an increasing alcohol series and embed-
ded in paraffin. Five micrometer sections were cut and 
transferred to Superfrost glass slides (Thermo Fisher, 
Waltham, USA). The sections were deparaffinized and 
either stained with haematoxylin and eosin or processed 
for immunohistochemistry. For the latter the slides were 
washed repeatedly in Tris buffered saline (TBS) and 
blocked for 30 min in 1 % bovine serum albumin (BSA)/
TBS. The slides were incubated with an anti-ki-67 anti-
body (Abcam, #ab15580, Cambridge, UK) over night at 
four degrees Celsius (1:100 in TBS). All following steps 
were performed at room temperature. After another 
washing step with TBS anti-rabbit-biotin antibody (Bio-
Science Products AG, Emmenbrücke, Switzerland) 
was added (1:100 in BSA/TBS) for 30  min. After wash-
ing with TBS, the slides were incubated with Streptavi-
din Peroxidase (Biospa, Milano, Itlay, 1:100 in TBS) for 
30  min. Another washing step with TBS followed, then 
the endogenous peroxidase was blocked by placing the 
slides in 0.3 % H2O2/TBS for 20 min. After another wash-
ing step with TBS the slides were incubated with 0.7 mg/
mL 3,3′-diaminobenzidine/H2O for 3–20 min. The slides 
were washed with dH2O and mounted with glycergel 
(Dako, Glostrup, Denmark).
Quantitative reverse transcriptase polymerase chain 
reaction (qRT‑PCR)
Twenty mg frozen tumor tissue was transferred to Mag-
NALyser Green Beads tubes (Roche, Basel, Switzerland) 
and 600 microliter lysis buffer (RNeasy Mini Kit, Qiagen, 
Venlo, The Netherlands) was added. Tissue homogeniza-
tion was carried out according to manufacturer’s instruc-
tions with a Precellys 24 Homogenizer (Bertin, Montigny 
le Bretonneux, France). The lysate was centrifuged for 
1  min at 11.000g and transferred to RNeasy Mini Spin 
columns (Qiagen). RNA extraction was performed 
according to manufacturer’s protocols. Five hundred 
ng of purified RNA were subsequently used for cDNA 
synthesis with QuantiTect Reverse Transcription Kit 
(Qiagen), which was carried out according to the manu-
facturer’s recommendations. QRT-PCR was performed 
with hydrolysis probes from a Universal Probe Library 
(Roche) on a LightCycler 480 (Roche). The PCR program 
consisted of an activation phase of 10  min at 95  °C fol-
lowed by 45 cycles with 15 s at 95 °C and 1 min at 60 °C. 
Data was analyzed with the LightCycler480 software 
and REST software (http://www.gene-quantification.de). 
Primer sequences are listed in Table 1.
Data analysis and statistics
For the measurement of tumor volumes (V) the follow-
ing formula was used: V = pi
6
× L×W
2; where L corre-
sponds to the length of the tumor and W to width of the 
tumor.
All groups consisted of at least five individuals.
Measurement raw data was transformed by square root 
transformation and 1-way ANOVA was performed on 
data sets of day zero, five and 14 after treatment.
Results
The HNSCC model in nude mice worked best with a 
subcutaneously injected inoculation volume of 100  μL 
ringer lactate solution containing 1.5  ×  106 CAL-
33 cells. While for the concentrations 1  ×  106 and 
2  ×  106 cells no exponential tumor growth phase was 
reached (Additional file  1: Fig.  S1 A,C), after injection 
of 1.5 × 106 cells solid tumors with a calculated average 
volume of 150  mm3 developed within 24  days (Addi-
tional file 1: Fig. S1 B).
The biodistribution profile established by spectro-
metric fluorescence measurements of mTHPC revealed 
that all formulations accumulated in the tumor but the 
distribution patterns were different for the three sub-
stances (Fig.  1). After Foscan injection the fluorescence 
in the tumor increased fast until 8 and then the curve 
reached a plateau. Tumor and skin accumulations were 
Table 1 Sequences of primers
Probe numbers relate to the Universal Probe Library (Roche)
GAPDH Glyceraldehyde 3-phosphate dehydrogenase; TACSTD2 Tumor-Associated Calcium Signal Transducer 2; MMP7 Matrix Metalloproteinase-7; ALDH1A3 Aldehyde 
Dehydrogenase 1 Family, Member A3; MKI67 Marker of Proliferation Ki-67; GLUT1 Glucose Transporter 1
Gene Primer forward 5′–3′ Primer reverse 5′–3′ Probe
Human GAPDH CAGCAAGAGCACAAGAGGAA GTGGTGGGGGACTGAGTGT #3
Human TACSTD AGAGAGGGAGTGAGAGAAATTAAGG GCGACTCCCTTTTCGTTCTT #23
Human MMP7 GCTGACATCATGATTGGCTTT TCTCCTCCGAGACCTGTCC #72
Human ALDH1A3 TGGTGGCTTTAAAATGTCAGG TATTCGGCCAAAGCGTATTC #53
Human MKI67 CCAAAAGAAAGTCTCTGGTAATGC CCTGATGGTTGAGGCTGTTC #39
Human GLUT1 CTTTTCGTTAACCGCTTTGG CGAGAAGCCCATGAGCAC #62
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rather similar in trend but after 8 h, 48 h and 72 h slightly 
higher tumor fluorescence could be detected. Therefore 
8 h was selected as the optimum drug–light interval for 
Foscan (Fig.  1a). Foslip accumulation in the tumor rose 
sharply until 12  h with the curve flattening afterwards. 
The detected fluorescence was higher in the tumor when 
compared to skin between 24 and 72  h. Accordingly 
24 h was chosen as ideal treatment timepoint for Foslip 
(Fig. 1b). Lipidots accumulated strongly in the skin, peak-
ing at 12  h after injection. Fluorescence accumula-
tion within the tumor was increasing over time but was 
delayed when compared to skin. Fourty eight hours after 
injection Lipidots started to be cleared from the skin 
while accumulation within the tumor persisted. Although 
accumulation in the tumor was not higher 72 h was cho-
sen as drug–light interval when less Lipidots were pre-
sent in the skin (Fig. 1c). As a result of these fluorescence 
biodistribution profiles, the drug–light interval selected 
and applied for all further in vivo experiments are 8 h for 
Foscan, 24 h for Foslip and 72 h for Lipidot.
HPLC analysis confirmed mTHPC accumulation in 
the tumor 72  h after injection of all drug formulations 
(Fig. 2). Concentrations of Lipidots and Foslip were com-
parable, while the mTHPC concentration was lower with 
the Foscan formulation at this time point. Kidneys as well 
as skin showed high accumulation with Lipidots and Fos-
lip and lower accumulation with Foscan. Foslip concen-
tration was also high in the spleen whereas Lipidots and 
Foscan were present in this organ to a much lower extent. 
Very low concentrations were found in the lung with all 
three formulations and no drug could be detected in the 
liver with either formulation at 72 h.
Therapeutic effects after PDT treatment, analyzed 
by tumor size measurements indicated a treatment 
response to all three drug formulations (Fig. 3). The best 
results were accomplished by Foslip induced PDT which 
finally resulted in complete tumor remission with both 
light doses (10 and 20  J/cm2; 100 mW/cm2) (Fig. 3a, b). 
Foscan-PDT was also effective but tumors stopped to 
decrease further in size after 12 days with the lower light 
dose of 10 J/cm2 (Fig. 3a). Tumor residues of around 40 % 
of the initial tumor volume (i.e. before treatment) were 
still present 14 days later with both light doses (Fig. 3a, 
b). Lipidots, although diminishing the tumor masses sig-
nificantly failed to decrease the tumor size further after 
Fig. 1 Spectrometric fluorescence measurements in skin and tumor 
after injection of Foscan (a), Foslip (b) and Lipidot (c)
Fig. 2 Tissue concentration of mTHPC (ng/mg wet tissue weight) 
72 h after injection, as determined by HPLC analysis
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6  days with the lower light dose (Fig.  3a). The higher 
light dose (20 J/cm2) resulted in continuous reduction of 
tumor masses down to around 60 % of the initial tumor 
volume (Fig.  3b). Fourteen days after treatment Foslip 
was significantly superior to both, Foscan and Lipidots at 
lower light doses (p < 0.05) and significantly superior to 
Lipidots at higher light doses (p < 0.01).
Fourty eight hours after Foscan and Foslip mediated 
PDT skin burns were visible at the irradiated spot with 
both light doses but only slight burns occurred after 
Lipidot-PDT, even with the higher light dose (Figs. 4, 5). 
One week after PDT necrotic tissue and crusts were vis-
ible with all three drug formulations at both light doses. 
Fourteen days after Foslip-PDT visible tumor masses 
had disappeared completely and the skin had healed 
with minimal scarring. Tumors treated with Foscan-
PDT had diminished significantly in size and the skin 
had started to heal but small crusts and residual tumor 
tissue remained. Lipidot-PDT treated tumors had also 
diminished in size after 14 days but with this formulation 
an outer rim of the tumor remained with a crust from 
destroyed tissue in the middle. Generally the destructive 
effects as well as the burning of the skin were more severe 
with the higher light dose in all cases which, however, did 
not seem to affect healing negatively.
A drop of body weight was observed in mice after Fos-
can and Foslip mediated PDT but more severe in case 
of Foscan (Fig.  6a). Also the higher light dose lead to a 
stronger body weight drop (Fig. 6b). Lipidots on the other 
hand did not result in any loss of body weight with nei-
ther light dose. If anything it delayed the body weight 
gain of the juvenile mice slightly (Fig. 6a, b).
A change in behavior of mice during and after admin-
istration of Foscan was apparent. The mice curled upon 
injection, which seemed to be painful to the rodents. 
Also during and after PDT the mice struggled and tried 
to avoid strongly to be touched, despite being treated 
with analgesics. Foslip and Lipidot injections as well as 
PDT seemed to be well tolerated with mice not showing 
any unusual behavior.
Histological analysis was in accordance with cali-
per measurements revealing vascularized vital CAL-33 
tumors in untreated mice (Fig.  7a). Fourty eight hours 
after Foscan mediated PDT the tumors showed clear fea-
tures of destruction with lamellar appearing tumor parts 
and flattened cells (Fig.  7a). Lipidot-PDT created the 
same lamellar features but a larger area in the outer part 
of the tumors appeared to be left intact (Fig. 7c). Foslip-
PDT, however, led to lamellar parts and strongly flattened 
cells throughout the whole tumor mass (Fig. 7d).
To distinguish between vital, proliferating cancerous 
and damaged tumor tissue a proliferation marker (ki-67) 
was used (Fig. 8). Antibody staining supported the tumor 
size measurements confirming diminished proliferation 
corresponding to less ki-67 expressing cells 48  h after 
PDT with all formulations. Foscan-PDT treated tumors 
showed little ki-67 positive cells when compared to 
untreated tumors after 48 h (Fig. 8b). Tumors after Lipi-
dot mediated PDT still exhibited several ki-67 positive 
cells but less than untreated controls (Fig. 8c) and tumors 
that had been subjected to Foslip-PDT exhibited no ki-67 
stained cells at all (Fig. 8d).
Histological and immunohistochemical analyses of 
tumors 14 days after treatment supported caliper meas-
urement data. Tumors which had been subjected to Fos-
lip-PDT were completely eradicated just leaving fibrotic 
scar tissue behind. Tumors after Foscan-PDT were not 
fully destroyed leaving some tumor tissue intact while 
the tumors after Lipidot-PDT were only partly destroyed 
with some cells positive for ki-67, thus still proliferating 
(data not shown).
Possible side effects of the treatments were investigated 
by analyzing livers, kidneys and spleens 48 h and 14 days 
after PDT. Liver damage was recognizable by deformed 
Fig. 3 Caliper measurements of tumor volume changes after PDT (day 0) with 10 J/cm2 (a) and 20 J/cm2 (b)
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Fig. 4 Images of tumors after PDT with 10 J/cm2. The irradiation area had a diameter of 1.5 cm (circle)
Fig. 5 Images of tumors after PDT with 20 J/cm2. The irradiation area had a diameter of 1.5 cm (circle)
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blood vessels and condensed nuclei of hepatocytes 48 h 
after Foscan and Foslip mediated PDT but not after 
Lipidot-PDT. However, the morphological changes were 
reversible as 14 days later all livers displayed similar mor-
phological appearance. No damage of other organs was 
detectable neither 48 h after nor 14 days after PDT.
Fig. 6 Body weight changes before and after PDT (at day 0) with 10 J/cm2 (a) and 20 J/cm2 (b)
Fig. 7 H&E stain of CAL‑33 tumors. a Untreated control tumor. Tumor 48 h after PDT with Foscan (b), Lipidot (c) and Foslip (d). Laser light irradiation 
20 J/cm2. Asterisk (b, c) : tumor tissue. a, d: only tumor tissue
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We tested possible expression changes of five genes 
(TACSTD, MMP7, ALDH1A3, MKI67, GLUT1) in 
tumors 48 h and 14 days after mTHPC and Lipidot medi-
ated PDT compared to untreated tumor controls (Fig. 9). 
Foslip-PDT destroyed the tumors completely and there-
fore no RT-PCR analysis was performed. MMP7 and 
ALDH1A3, that are stem cell markers for squamous 
cell carcinoma [29, 30], were not expressed in neither 
treated nor untreated tumors. TACSTD as marker for 
tumor aggressiveness [31] was not present in relevant 
abundance either. GLUT1, that may reflect the grade of 
malignancy [32], showed upregulation 48 h after mTHPC 
mediated PDT but not after Lipidot-PDT. However, these 
alterations were not present 14 days later. The prolifera-
tion marker gene MKI67 [33] did not reveal a significant 
Fig. 8 Ki‑67 immunohistochemistry for CAL‑33 tumors. a Untreated control tumor. Tumor 48 h after PDT with Foscan (b), Lipidot (c) and Foslip (d). 
Laser light irradiation 20 J/cm2
Fig. 9 QRT‑PCR data from tumors 48 h and 14 days after mTHPC‑PDT 
and Lipidot‑PDT. Laser light irradiation 20 J/cm2
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expression change although it was expressed to a slightly 
higher extent in tumors after Lipidot-PDT when com-
pared to tumors that had been exposed to Foscan-PDT.
Discussion
Many preclinical studies provide evidence that PDT has 
great potential as anti-cancer modality. However, the 
hurdles of limited solubility of photosensitizers and pho-
tosensitivity of patients hamper routine use in the clinics 
and made encapsulation of PSs into nanocomposites an 
attractive option. Recently, the successful encapsulation 
of mTHPC in several nanocarriers had been described, 
such as polymeric nanoparticles [34, 35] and calcium 
phosphate nanoparticles [36]. In a similar approach in 
our former studies we presented the successful encap-
sulation of mTHPC into fully biocompatible and biode-
gradable lipid nanoemulsions and showed first data in 
monolayer cells [23, 24]. In our subsequent investiga-
tions in multicellular tumor spheroids we identified a 
formulation with a high mTHPC payload that featured 
the same excellent PDT effects as the free mTHPC but 
with a reduced dark toxicity (Lipidots) [25]. This nanoe-
mulsion consists of a phospholipid (lecithin) monolayer, 
protected by a PEG-shell with a soybean/wax core, where 
mTHPC is incorporated. The average particle diameter of 
the most promising formulation was 50 nm with a PDI of 
0.17 and a zeta potential close to −7 mV.
In the present study we now report for the first time on 
in vivo PDT with these novel PS-loaded Lipidots using a 
cancer xenograft nude mouse model. To better compare 
PDT effects of Lipidots, we included treatments with the 
conventional and approved mTHPC formulation Foscan 
[37–39] as well as the liposomal mTHPC formulation, 
Foslip, that already gave promising results in the treat-
ment of cancer in cats [28, 40] and mice [40–42]. The 
lipsomes in the Foslip solution had an average particle 
size of 135 nm and a PDI of 0.089 with a zeta potential of 
around -13 mV.
One of the prerequisites for successful PDT is a high 
accumulation of the PS within the tumor site. While it 
is known that PSs are preferentially taken up by cancer 
cells compared to normal cells [13], in vivo intratumoral 
doses of PSs may actually often be low due to solubility 
problems and/or interactions with plasma proteins [42]. 
Increasing the PS dose, however, bears the risk of high 
circulating PS amounts and photosensitivity of skin and 
eyes.
We here showed that after intravenous injection Fos-
can accumulates in cancer xenografts and that treatment 
with Foscan-PDT significantly reduced tumor volumes 
under the selected conditions. However, our histological 
analyses confirmed that Foscan-mediated PDT did leave 
tumor residues behind in most cases. These residues were 
still present 14 days after treatment. Our HPLC data indi-
cated a lower cancer accumulation of Foscan when com-
pared to the other formulations 72 h after injection. The 
low accumulation, probably due to solubility problems, 
might be an explanation for the suboptimal PDT success. 
Also the other organs presented with less mTHPC con-
tent in the case of Foscan. Apart from solubility issues, 
an interaction with plasma proteins or, when taking into 
account the late time point of the HPLC measurement, 
faster systemic clearance could be at work.
Immunohistochemistry with ki-67 antibodies revealed 
that after Foscan-PDT, proliferating cells were still pre-
sent in these samples but not more than in untreated 
cancers. Since elevated ki-67 is thought to be indicative 
for an unfavorable prognosis in head and neck cancers 
[43], incomplete PDT apparently did not select for this 
phenotype. To further characterize surviving tumor cells 
after PDT with Foscan, we performed qPCR studies for 
selected genes. Gene expression analyses revealed that 
cancer stem cell markers MMP7 and ALDH1A3 were 
neither transcribed before nor after PDT in CAL-33 cells. 
However, one genetic marker of tumor aggressiveness, 
GLUT1, was upregulated after Foscan-PDT. To the best 
of our knowledge, this is the first report on an increase 
of GLUT1 mRNA due to Foscan-PDT. The upregulation 
may have been the result of a PDT-related acute stress 
response as GLUT1 has previously been described as cell 
stress response gene [44]. However, 14  days after Fos-
can-PDT GLUT1 expression returned to control levels, 
suggesting that no permanent cell transformation into 
a GLUT1-related aggressive subtype had taken place. 
Although in our model remaining tumor cells did not 
start to proliferate in an aggressive manner we cannot 
exclude that they changed their phenotype. It is known 
that PDT can cause resistance in tumor cells under cer-
tain conditions and an acute stress response is one of 
them [11]. Thus, it would be interesting to investigate 
PDT resistance mechanisms in a follow up study by irra-
diating the tumors repeatedly.
Despite the different nature of the nanoformulations 
both, Lipidots and Foslip, accumulated in the xenografts 
and could reduce tumor volumes significantly after PDT. 
The observed slower cancer accumulation rate of Lipi-
dots compared to Foscan is in line with our previous 
in  vitro results from cancer spheroids [25] where pen-
etration of Lipidots into the spheroid core was delayed. 
However, while tumor residues were still present after 
Lipidot-PDT, Foslip mediated PDT could eradicate the 
cancers completely. After Lipidot-PDT primarily the 
outer rim of the tumor seemed to be left intact, which 
was confirmed by histological analyses. Interestingly, 
we have observed a similar outcome already in our pre-
vious in  vitro study with multicellular tumor spheroids 
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[25] where spheroids were dying in the center but outer 
cell layers were left intact. The reason for this phenom-
enon is not clear yet. We can only speculate that e.g. the 
cells in the center are more susceptible to PDT due to 
poor nutrient supply or that in the outer layers a kind of 
quenching effect might occur. Another possible explana-
tion could be that the particles stay intact when entering 
the cell and are therefore less accessible for light activa-
tion. Ki-67 staining also revealed proliferating cells after 
Lipidot PDT as seen in the case of Foscan, while after 
Foslip PDT no such cells were present. QRT-PCR data 
showed no GLUT1 upregulation after PDT for neither of 
the particles, indicating that encapsulation changes cer-
tain cellular effects of the PS in  vivo. This result is well 
in line with our previous in vitro results where we could 
show that encapsulation into Lipidots can dampen the 
expression response after mTHPC mediated PDT for a 
wide range of genes [25]. With regard to drug resistance 
encapsulation might thereby offer an advantage over the 
use of the free formulation.
Both particles, Lipidots and Foslip, contain the same 
drug and drug amounts were kept constant for all for-
mulations. Furthermore, 72 h after injection quantitative 
HPLC analysis showed similar mTHPC amounts in the 
xenograft for both nanoformulations. According to these 
observations the difference in therapy outcome is most 
likely due to the nanoparticle itself.
While in the Foscan solution mTHPC is solubilized by 
use of a solvent consisting of propylene glycol/alcohol in 
the liposomes the PS, because of its amphiphilic nature, 
is entrapped in the phospholipid bilayer. In contrast in 
the nanoemulsion (Lipidots) with a phospholipid mon-
olayer hull the PS is incorporated into the oil/wax core. 
Due to the different structure cells might interact with 
each nanoparticle in a different way and might cause or 
might not cause PS release by an uptake event. Further-
more, it is well known that the nature of the particle can 
have a major impact on its later subcellular localization, 
which is an import factor for the success of PDT [45]. 
Additionally both particles consist of different lipids 
and contain different lipid amounts in their formulation 
which is fivefold higher in the case of Lipidots.
From our biodistribution studies we have chosen 
drug–light intervals of 8 h and 24 h for Foscan and Fos-
lip, respectively. To avoid high PS levels in the skin, for 
Lipidots, we extended the drug–light interval to 72  h. 
The idea behind this approach was to minimize the 
damage to healthy tissue by irradiation and to reduce 
the risk of subsequent scarring. However, with care-
ful shielding as in our study, an earlier treatment time 
point might have been advantageous, since it has been 
shown that the drug–light interval determines in which 
compartment the PS accumulates preferentially. It has 
been demonstrated e.g. by Lassalle et  al. [46] that at 
early time points Foslip is circulating mostly within the 
blood stream, only after several hours it can reach the 
tumor site and at later time points it is mainly located 
within the cancers of mammary carcinoma bearing nude 
mice. It might have been the case that at the late treat-
ment time point blood vessels were not affected by PDT, 
which would have been necessary to avoid subsequent 
tumor regrowth. In the present study, biodistribution was 
investigated by two complementary methods, i.e. spec-
trometric fluorescence in vivo measurements and HPLC 
endpoint analyses. Clearly, certain discrepancies between 
results of these methods arose that may have been caused 
by different optical measurement conditions after injec-
tion of the formulations that were most likely influenced 
by differences in subcellular distribution, aggregation 
behavior or localization of the PS within the tissue. It is 
well known that the nature of the nanocarrier may have a 
strong influence on these parameters, which can in turn 
lead to decreased detectability by methods that rely on 
fluorescence and might ultimately hamper a treatment 
response. Considering the different size and composition 
of the nanocarriers a distinctively different biodistribu-
tion profile was to be expected.
However, differences in the detectability made it very 
difficult to predict the optimal treatment time point. 
On the other hand, use of HPLC detection for all treat-
ment time points would have called for a huge amount 
of rodents, which we deliberately refrained from. Never-
theless a better correlation between fluorescence meas-
urements and HPLC should be established for future 
experiments.
Furthermore, it has to be stated that for successful 
PDT, dosimetry, that means the appropriate drug and 
light dose, as well as the optimal drug–light interval 
are of uttermost importance. In the case of Foscan and 
Foslip appropriate treatment schemes had already been 
established previously [28, 46], while for Lipidots no 
such protocol exists. We therefore cannot exclude that 
the drug–light interval used in our mouse model was 
not optimal for all substances, especially for the Lipidot 
formulation.
A factor which is often neglected in the therapy of can-
cer patients is their overall constitution. Because their 
body is already massively weakened by the disease it is of 
uttermost importance that the administered drugs do not 
unnecessarily deteriorate their health status by causing 
additional side effects. When it comes to treatment toler-
ance Lipidots were clearly performing best. Convenient, 
painless injection, no change in behavior of mice and no 
body weight loss indicate a highly biocompatible nano-
formulation. In contrast Foscan was problematic in this 
regard, causing painful injections and severe weight loss. 
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Foslip was also superior to Foscan in this matter. Injec-
tions were unproblematic; however a slight weight loss 
was apparent. Furthermore our HPLC data showed high 
spleen accumulation only for Foslip, which leads to the 
conclusion that it is particularly susceptible to elimina-
tion from the blood stream via the reticuloendothelial 
system. Given the fact, that the particles are not pro-
tected by a PEG layer, it is not surprising that they are 
inferior to Lipidots in this regard.
As evidenced by histology, both Foslip and Foscan 
caused acute liver toxicity while the Lipidots seemingly 
had no such effect. However, 14  days after treatment 
all livers morphologically recovered. This is in line with 
our HPLC data which showed that already after 72 h no 
mTHPC was detectable in the livers, pointing towards a 
fast liver clearance as it had already been shown by Rov-
ers et al. [47].
The high skin accumulation of Lipidots after systemic 
injection was a surprising finding as not much can be 
found in the literature concerning this phenomenon. 
Moreover no real explanations are given. However, many 
studies about topical nanoparticle administration and 
skin distribution exist. One explanation for prolonged 
skin accumulation in a study by Mittal et al. is e.g. a pos-
sible accumulation in hair follicles [48]. It would be very 
interesting to study the distribution of Lipidots in the 
mouse skin to investigate if this is the case and to deter-
mine their exact localization. These results might further 
clarify the interestingly different particle behaviour of 
both nanoformulations.
We also detected high mTHPC accumulation in the 
kidney with both nanoformulations. Bearing in mind that 
both intact particles are generally regarded as being too 
big for fast effective renal clearance [49] it is not surpris-
ing to still find mTHPC traces in this organ after 72 h, as 
clearance may be retarded through encapsulation. There-
fore it can be assumed that free mTHPC will be cleared 
faster from the kidneys. Furthermore the overall biodis-
tribution of mTHPC is expected to be worse due to solu-
bility issues and unspecific aggregation.
Interestingly, despite the high mTHPC load, the kidney 
did not show signs of histological impairment, neither 
did other organs. Although we did not test for specific 
markers of organ function, we propose that none of the 
mTHPC formulations used cause severe side effects in 
kidney, spleen, lung and liver.
Conclusions
In conclusion we could confirm in our study the supe-
riority of nanoformulations to the free PS mTHPC. 
Bearing in mind that the free substance is related to 
several issues such as poor bioavailability, solubility and 
increased photosensibility of patients the development of 
a potent nanoformulation is a necessity. We could show 
that Foslip on the one hand is very effective in destroying 
the tumors itself. However, because the Lipidots’ biocom-
patibility is outstanding and superior to the liposomes we 
declare further investigations and protocol optimization 
a priority in the future.
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